Spironolactone for resistant hypertension in advanced chronic kidney disease—red, amber or green?
Open Access
- 11 February 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (8), 1288-1290
- https://doi.org/10.1093/ndt/gfz299
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney diseaseKidney International, 2019
- 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of HypertensionJournal of Hypertension, 2018
- Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER StudyAmerican Journal of Nephrology, 2018
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2018
- Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patientsHeart, 2018
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialThe Lancet, 2017
- The double challenge of resistant hypertension and chronic kidney diseaseThe Lancet, 2015
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialThe Lancet, 2015
- Aldosterone antagonists for preventing the progression of chronic kidney diseaseEmergencias, 2014
- Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney Disease PatientsJournal of the American College of Cardiology, 2013